Oxacillin sodium monohydrate destined for sterile dry-fill injection is handled as a sterile crystalline powder after aseptic recrystallization from a depyrogenated Water for Injection solution. The filtered solution is passed through a 0.10 µm polyvinylidene fluoride membrane before programmed cooling at 2 °C/h from 20 °C to −5 °C; the resulting crystals are washed with cold acetone and vacuum-dried at 30 °C for 8–12 h. The dried sterile powder is milled in a nitrogen-purged pin mill with jacket temperature ≤20 °C and filled into depyrogenated Type I glass vials. Vial depyrogenation is performed at 250 °C for ≥30 min; elastomer stoppers are autoclaved at 121 °C for 15 min and dried to residual moisture ≤0.4%. Filling takes place in an EU GMP Annex 1 Grade A zone with unidirectional airflow 0.45 m/s ±20% and ISO 14644-1 class 5 particle limits. Fill weight for a nominal 1.0 g fill is controlled on an in-line checkweigher with alarm at ±2.5% and release at ±5%. The terminal product is a white to off-white sterile dry powder for reconstitution to 250 mg/mL with Water for Injection; reconstituted pH is 6.0–7.5. Release tests include USP <71> sterility, USP <85> bacterial endotoxins, USP <791> pH, and USP <921> Karl Fischer moisture at ≤1.0% w/w. Water vapor transmission through the stopper-vial seal is monitored during stability at 25 °C/60% RH because moisture ingress above 1.5% accelerates hydrolysis to penicilloic acid and produces visible collapse of the powder plug.

What Limits Direct Compression of Oxacillin Tablets on High-Speed Rotary Presses?

Direct compression of oxacillin sodium monohydrate into 250 mg oxacillin-equivalent tablets fails on a 16-station rotary press when the crystalline API has a D90 greater than 150 µm, producing weight variation above ±7.5% and content uniformity failures under USP <905>. A production-scale wet granulation formula comprises oxacillin sodium monohydrate 40.0% w/w, microcrystalline cellulose PH-102 38.5% w/w, lactose monohydrate 15.0% w/w, crospovidone 4.0% w/w, colloidal silicon dioxide 1.0% w/w, and magnesium stearate 1.5% w/w. The binder is 5% w/w povidone K30 in purified water, added to a 25 kg high-shear granulator bowl at 0.4 kg/min with impeller speed 200 rpm and chopper speed 1,500 rpm; wet mass is passed through a 1.18 mm screen. Tray drying at 50 °C for 6–8 h reduces loss on drying to 1.2–2.0%; dried granules are milled through 0.800 mm and lubricated in a V-blender at 12 rpm for 3 min. Lubrication beyond 5 min shears magnesium stearate and causes picking on the tablet punch faces. Tablets are compressed to hardness 80–120 N, friability ≤0.8% by USP <1216>, disintegration ≤15 min by USP <701>, and dissolution not less than 75% at 30 min by USP <711>. The terminal dosage form is a film-coated tablet; a non-aqueous ethylcellulose lipid coating is applied at 3% w/w weight gain to limit moisture ingress without subjecting the beta-lactam to aqueous coating conditions. The granulation must be compressed within 24 h after drying; stored granule blends exposed above 60% RH show hardness drift exceeding 15% and an increase in total impurities above 0.5%. Assay is by HPLC under USP <621> with a C18 column, detection at 225 nm, and mobile phase of 0.01 M phosphate buffer/acetonitrile 60:40.

For hard gelatin capsule production, low-shear blending is selected because oxacillin sodium monohydrate crystals fracture under high-shear mixing and generate fines that depress bulk density and increase capsule fill-weight drift. A 500 mg oxacillin-equivalent veterinary capsule formula contains active ingredient 55.0% w/w, anhydrous lactose 35.0% w/w, pregelatinized starch 9.0% w/w, croscarmellose sodium 0.5% w/w, colloidal silicon dioxide 0.5% w/w, and sodium stearyl fumarate 1.0% w/w. Sodium stearyl fumarate is used instead of magnesium stearate to reduce hydrophobic coating of the beta-lactam and prevent lubrication-dependent dissolution delay. Blending is performed in a tumble blender at 15 rpm for 20 min; the powder is filled into opaque size #0 hard gelatin capsules using a dosator-type capsule filler with fill weight target ±3.0% and individual capsule weight coefficient of variation ≤1.2%. In-process moisture is controlled by USP <921> Karl Fischer at ≤2.0% w/w before encapsulation; croscarmellose sodium is held at 0.5% w/w because higher levels introduce bound water into the capsule headspace and accelerate beta-lactam ring hydrolysis. The terminal product is a sealed hard gelatin capsule for oral administration. Release includes microbial enumeration per USP <61> and absence of specified organisms per USP <62>, potency by HPLC per USP <621>, and dissolution using USP <711> apparatus II at 75 rpm in 900 mL of phosphate buffer pH 6.8, with a limit of not less than 75% dissolved at 45 min. Modified-release coating is avoided because delayed passage beyond the duodenum reduces beta-lactam absorption and increases colonic hydrolysis; immediate-release dissolution is therefore a critical quality attribute.

When Oxacillin Sodium Is Formulated as a Water-Soluble Powder for Drinking Water Administration

Buffered water-soluble powder is filled into foil-lined sachets for use in calf milk replacer or drinking water under veterinary supervision. A 10 kg batch comprises oxacillin sodium monohydrate 50.0% w/w, anhydrous citric acid 24.0% w/w, sodium citrate dihydrate 20.0% w/w, lactose monohydrate 5.0% w/w, and colloidal silicon dioxide 1.0% w/w. The citric acid–sodium citrate buffer pair maintains reconstituted pH at 6.5–7.0 at 10 g/L in potable water; outside this range, hydrolysis to penicilloic acid increases markedly. Citric acid and lactose are first milled through a 0.500 mm screen to prevent agglomerates; the active is added geometrically and blended in a double-cone blender at 15 rpm for 20 min. After reconstitution in potable water at 25 °C, the solution is used within 24 h; at 30 °C, published kinetic data for reconstituted penicillin solutions indicate a half-life below 8 h, so refrigeration is required. The sachet is packed under low humidity ≤30% RH; moisture content by USP <921> is ≤1.5%. In-line filtration through a 150 µm screen removes insoluble carbonate precipitates that can form in hard water containing calcium and magnesium above 150 mg/L as CaCO₃. The terminal product is a free-flowing white powder for reconstitution. Batch release includes blend uniformity by sampling 10 points with acceptance value ≤15 per USP <905>, potency and related substances by HPLC, and microbial quality per USP <61>/<62>. Process controls under 21 CFR 211.110 document blend time, sachet seal temperature, and fill weight to assure batch homogeneity.

Intramammary infusion processing window narrows at vehicle temperatures above 45 °C.

In a thickened mineral-oil/white-petrolatum intramammary vehicle, oxacillin sodium monohydrate is dispersed for dry-cow therapy. Because the antibiotic is practically insoluble in lipophilic carriers, jet milling reduces particle size to D90 ≤15 µm to prevent settling and teat canal irritation; particle size is verified by laser diffraction per ISO 13320:2020. The vehicle phase contains heavy mineral oil 69.0% w/w, white petrolatum 15.0% w/w, aluminum stearate 2.0% w/w, sorbitan monooleate 1.0% w/w, and colloidal silicon dioxide 5.0% w/w; active ingredient is incorporated at 8.0% w/w. The oil phase is heated to 40–45 °C in a jacketed stainless-steel vessel; temperatures above 50 °C are not used because beta-lactam ring opening proceeds even without aqueous moisture. The vehicle is filtered through a 0.10 µm absolute-rated membrane at 40 °C; sterile active is dispersed under vacuum with an in-line rotor-stator mixer at 3,500 rpm for 15 min. The suspension is cooled to 25 °C with sweep agitation at 20 rpm, and viscosity is controlled at 20–50 Pa·s at 20 °C to hold D90 particles in suspension without gelation. Filling into 10 mL single-dose intramammary polyethylene cannulas is performed aseptically; fill volume is set at 10.5 mL with ±0.2 mL limit to ensure full dose expression. The terminal product is an opaque oily suspension for intramammary infusion. Sterility release by USP <71>, content uniformity of dispensed dose by USP <905>, and cannula tip-force are monitored. The formulation is incompatible with sulfamethazine-containing intramammary suspensions in the same infusion sequence; published compatibility data for this specific combination are limited, and separate treatment intervals are required when mixed protocols are unavoidable.

Feed Premix Granulation Without Steam Conditioning

For fluid-bed granulation intended for calf milk replacer, oxacillin sodium monohydrate is incorporated into a 5.0% w/w feed premix by wet granulation rather than steam-conditioned pelleting. Steam conditioning at 70–85 °C in a pellet mill exposes the beta-lactam to heat and moisture and causes potency loss; published data for oxacillin in steam-pelleted feed at low inclusion are limited, so post-pelleting application or dry blending into the finished feed is used. A 50 kg granulation batch consists of oxacillin sodium monohydrate 5.0% w/w, pregelatinized starch 55.0% w/w, lactose monohydrate 35.0% w/w, and hydroxypropyl methylcellulose 5.0% w/w. The binder solution is 10% w/w HPMC in purified water, sprayed in a fluid-bed granulator with inlet air temperature 55 °C, product temperature 32–35 °C, and spray rate 0.8 L/h per kg. Granules are dried to residual moisture 1.0–2.5%, with D50 180–250 µm and D90 ≤400 µm, then sieved through 0.710 mm before packing in heat-sealed low-density polyethylene liners. Final blending into calf milk replacer is performed in a ribbon blender at 15 rpm for 10 min; demixing is prevented by matching the premix particle size to the milk replacer carrier within a ratio of 3:1. The terminal product is a free-flowing granulated premix for on-farm mixing. Release includes potency and related substances by HPLC per USP <621>, moisture by USP <921>, microbial contamination per USP <61>/<62>, and blend uniformity with acceptance value ≤15. A stability-indicating HPLC method quantifies penicilloic acid, penillic acid, and total unspecified impurities below 1.0% each; stored samples at 25 °C/60% RH are tested at 0, 1, 3, and 6 months, with specification of assay not less than 90% of label and moisture not more than 2.5%.